B. Riley Issues Pessimistic Forecast for InfuSystem Earnings

InfuSystem Holdings, Inc. (NYSE:INFU) – Equities researchers at B. Riley decreased their FY2024 EPS estimates for shares of InfuSystem in a research report issued to clients and investors on Thursday, November 7th. B. Riley analyst K. Bauser now anticipates that the company will earn $0.15 per share for the year, down from their prior estimate of $0.17. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for InfuSystem’s current full-year earnings is $0.17 per share. B. Riley also issued estimates for InfuSystem’s Q4 2024 earnings at $0.08 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.31 EPS and FY2026 earnings at $0.43 EPS.

Separately, StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday.

InfuSystem Trading Up 6.4 %

Shares of INFU stock opened at $7.81 on Monday. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64. The stock’s 50 day simple moving average is $6.59. The stock has a market cap of $166.47 million, a P/E ratio of 130.17 and a beta of 1.45. InfuSystem has a 12-month low of $5.74 and a 12-month high of $10.99.

InfuSystem (NYSE:INFU) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The firm had revenue of $33.70 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of InfuSystem by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock worth $9,288,000 after acquiring an additional 18,432 shares during the period. Sequoia Financial Advisors LLC acquired a new stake in InfuSystem in the second quarter valued at $272,000. First Eagle Investment Management LLC increased its position in shares of InfuSystem by 12.7% in the first quarter. First Eagle Investment Management LLC now owns 605,235 shares of the company’s stock valued at $5,187,000 after buying an additional 68,021 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of InfuSystem by 6.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after buying an additional 5,391 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of InfuSystem by 52.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company’s stock worth $178,000 after buying an additional 8,917 shares in the last quarter. 71.13% of the stock is currently owned by institutional investors and hedge funds.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.